About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Liver Disease Clinical Trials in Chicago | 15 Studies

Clinical Trials Liver DiseaseChicago

Liver Disease Clinical Trials in Chicago

Find 15 clinical trials for liver disease near Chicago, Illinois. Connect with research centers in your area.

All Liver Disease trials nationwide All trials in Chicago

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 1-15 of 15 trials

CompletedStudy Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisThe primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults…NCT03439254·Dothan, Alabama and 191 others

Liver Disease Trials in Other Cities

New York Los Angeles Houston Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

RecruitingA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASHThis is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.NCT06528314·Birmingham, Alabama and 330 others

Active not recruitingA Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and FibrosisA double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or reduces fibrosis on liver biopsy…NCT03900429·Birmingham, Alabama and 246 others

TerminatedSimtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASHThe primary objective of this study is to evaluate the safety and efficacy of SIM (formerly referred to as GS-6624) in adults with compensated cirrhosis due to Non-Alcoholic…NCT01672879·Phoenix, Arizona and 58 others

RecruitingA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASHThe study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH…NCT06419374·Birmingham, Alabama and 325 others

CompletedStudy of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)The goal of this clinical study is to understand whether the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), cause…NCT04971785·Birmingham, Alabama and 241 others

TerminatedStudy to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver FibrosisThis is a Phase 2, randomized, double-blind, placebo-controlled, multicenter, multinational, dose-finding study evaluating the efficacy of three treatment doses of CC-90001…NCT04048876·Phoenix, Arizona and 141 others

CompletedA Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease PatientsA double-blind placebo controlled randomized Phase 3 study to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching…NCT04197479·Birmingham, Alabama and 76 others

CompletedStudy to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)The primary objectives of this study are: * To assess the safety and tolerability of selonsertib (SEL), firsocostat (FIR) and cilofexor (CILO), administered alone or in…NCT03449446·Chandler, Arizona and 100 others

TerminatedRollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic SteatohepatitisThis rollover study will provide open-label treatment with cenicriviroc and will assess the long-term safety of continued treatment with cenicriviroc in participants who…NCT03059446·Dothan, Alabama and 70 others

CompletedStudy of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)A multi-center evaluation of aldafermin in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis.NCT04210245·Glendale, Arizona and 48 others

TerminatedSafety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)The primary objective of this study is to evaluate whether SIM (formerly referred to as GS-6624) is effective at preventing the histologic progression of liver fibrosis and the…NCT01672866·Phoenix, Arizona and 67 others

CompletedStudy of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver FibrosisThe purpose of this study was to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with…NCT03517540·Chandler, Arizona and 64 others

TerminatedSafety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce associated complications in adults with cirrhosis…NCT03053063·Chandler, Arizona and 282 others

UnknownEmricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH CirrhosisThis is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of emricasan in improving event-free survival based on a composite…NCT03205345·Chandler, Arizona and 75 others

Other Conditions in Chicago

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia